| DB ID | MyCo_5493 |
| Title | Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial |
| Year | 2013 |
| PMID | 23639612 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This study is registered with ClinicalTrial.gov, number NCT00163722. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | 18S rRNA gene |
| Biomarker Full Name | 18S rRNA gene |
| Biomarker Type | Diagnostic |
| Biomolecule | Gene |
| Geographical Location | Australia |
| Cohort | 240 eligible patients were recruited from six Australian centres between Sept 30, 2005, and Nov 19, 2009. 122 were assigned the standard diagnostic strategy and 118 the biomarker-based diagnostic strategy. 39 patients (32%) in the standard diagnosis group and 18 (15%) in the biomarker diagnosis group received empirical antifungal treatment (diff erence 17%, 95% CI 4–26; p=0·002). |
| Cohort No. | 240 |
| Age Group | > 18 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The risk of death from invasive aspergillosis in patients undergoing allogeneic stem-cell transplantation or chemotherapy for acute leukaemia is high, largely because of delays in diagnosis by culture and histology. Consequently, prophylaxis is used and empirical treat- ment with antifungal drugs is given to neutropenic patients suspected of having an invasive fungal infection because of persistent fevers despite treatment with broad-spectrum antibacterial drugs. Although this strategy has reduced mortality from invasive asper gillosis, the drawbacks include breakthrough invasive fungal disease, drug interactions, emergence of anti fungal resistance, and overtreatment with expensive antifungal drugs. |
| Technique | PCR |
| Analysis Method | PCR Based |
| ELISA kits | Platelia Aspergillus enzyme immunoassay (PA-EIA; Bio-Rad,France) |
| Assay Data | None |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA, PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
